Search | Clinical Trials Finder

Conditions: Meniscus Tear, Meniscus Lesion, Cartilage Injury
Interventions: Ceftriaxone, Placebo; Drug · Other
Lead sponsor: Austin V Stone; Other
Eligibility: 18 Years to 55 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Lyme Disease, Lyme Neuroborreliosis
Interventions: ceftriaxone; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1999
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteomyelitis
Interventions: oral antibiotics, intravenous antibiotics; Drug · Procedure
Lead sponsor: Julio Ramirez; Other
Eligibility: 18 Years to 100 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Gonorrhea
Interventions: Delafloxacin, Ceftriaxone; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 15 Years and older
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 25
States / cities: Birmingham, Alabama • Chula Vista, California • La Mesa, California + 21 more

Conditions: Community Acquired Pneumonia in Children
Interventions: Ampicillin for Injection, Ceftriaxone for Injection, Amoxicillin, Ampicillin / Sulbactam Injection, Amoxicillin-clavulanate, Clindamycin, Cefprozil, Levofloxacin; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 3 Months to 18 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Community-acquired Bacterial Pneumonia
Interventions: Solithromycin, Standard of Care; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 2 Months to 17 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 21
States / cities: Little Rock, Arkansas • Los Angeles, California • Sacramento, California + 18 more

Conditions: Pregnancy
Interventions: Ceftriaxon, Benzathine penicillin G; Drug
Lead sponsor: International Maternal Pediatric Adolescent AIDS Clinical Trials Group; Network
Eligibility: Female only
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Los Angeles, California • Chicago, Illinois • Stony Brook, New York + 2 more

Conditions: Community-Acquired Pneumonia (CAP)
Interventions: IV azithromycin, ceftriaxone, oral azithromycin, IV levofloxacin, oral levofloxacin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 22
States / cities: Birmingham, Alabama • Long Beach, California • Sylmar, California + 18 more

Conditions: Gonorrhea Male
Interventions: Cefixime, Ceftriaxone, Ciprofloxacin, Neisseria gonorrhoeae strain FA1090, Meningococcal Group B Vaccine, Influenza Vaccine, Tetanus-diptheria Vaccine; Drug · Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: E Coli Infection, ESBL Producing E.Coli
Interventions: Cefotetan, Carbapenems, Beta Lactam Antibiotics; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Chlamydia
Interventions: ceftriaxone, Azithromycin; Drug
Lead sponsor: Harold Wiesenfeld; Other
Eligibility: 15 Years to 35 Years · Female only
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 4
States / cities: Pittsburgh, Pennsylvania

Conditions: Bipolar Depression
Interventions: ceftriaxone, Saline solution; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Appendicitis, Cholecystitis, Cross Infection, Diverticulitis, Peritonitis
Interventions: tigecycline, ceftriaxone sodium + metronidazole; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 467 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 46
States / cities: Mobile, Alabama • Laguna Hills, California • Los Angeles, California + 38 more

Conditions: Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity, Antibiotic Allergy, Beta Lactam Adverse Reaction, Drug-Induced Anaphylaxis, Cephalosporin Reaction
Interventions: Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge, Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge, Amoxicillin double-blind placebo-controlled drug challenge; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 3 more

Conditions: Prosthetic Joint Infections of Hip, Prosthetic Joint Infections of Knee, Infected Spacers
Interventions: CEM-102, IV or Oral standard of care antibiotics, Rifampin; Drug
Lead sponsor: Arrevus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 13
States / cities: Sarasota, Florida • Tamarac, Florida • Savannah, Georgia + 8 more

Conditions: Infections
Interventions: Cephalosporin or clindamycin/vancomycin antibiotics.., Vancomycin and Tobramycin antibiotics.; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 90 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Post-Treatment Lyme Disease
Interventions: Ceftriaxone (Rocephin®), Dextrose 5% (D5W); Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: East Syracuse, New York

Conditions: HIV Infections, Neurosyphilis
Interventions: Penicillin G potassium, Ceftriaxone sodium; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 42
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 23 more

Conditions: Gonorrhea
Interventions: Gepotidacin, Ceftriaxone, Azithromycin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older
Enrollment: 628 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 13
States / cities: Los Angeles, California • Palm Springs, California • DeLand, Florida + 10 more

Conditions: Infections, Community Acquired Pneumonia
Interventions: Ceftaroline fosamil, Ceftriaxone, amoxicillin clavulanate; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 2 Months to 18 Years
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 13
States / cities: Long Beach, California • Oakland, California • Orange, California + 10 more

Conditions: Out-Of-Hospital Cardiac Arrest, Pneumonia
Interventions: Standard of care without prophylaxis, Antibiotic prophylaxis; Drug
Lead sponsor: David J. Gagnon; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Portland, Maine

Conditions: Pneumonia, Bacterial
Interventions: Sulopenem and PF-03709270, Ceftriaxone and amoxicillin/clavulanate; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 12
States / cities: Chula Vista, California • Oceanside, California • Moline, Illinois + 4 more

Conditions: Pelvic Inflammatory Disease
Interventions: Ceftriaxone, Doxycycline, Metronidazole, Placebo Oral Capsule; Drug
Lead sponsor: Harold Wiesenfeld; Other
Eligibility: 15 Years to 40 Years · Female only
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Preterm Premature Rupture of Membrane, Pregnancy, High Risk, Preterm Birth
Interventions: Ceftriaxone 1000 MG, Clarithromycin 500mg, Metronidazole 500 mg, Ampicillin 2 GM Injection, Amoxicillin 250 MG, Azithromycin, Erythromycin; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Columbus, Ohio • Galveston, Texas

Search by objective public record fields.

PROPER Trial of Pain and Inflammation After Knee Arthroscopy

Brain Imaging and Retreatment Study of Persistent Lyme Disease

Patients Response to Early Switch To Oral:Osteomyelitis Study

Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea

Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia

Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy

Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia

Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae

Cefotetan Therapy for Escherichia Coli Infections

Chlamydia Trachomatis Immunology and Vaccinology Study

Ceftriaxone in the Management of Bipolar Depression

Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Safety and Efficacy of CEM-102 With Rifampin Compared to Standard Therapy in Patients With Prosthetic Joint Infections or Spacer Infection

Vancomycin and Tobramycin Powder Use in Acute Open Fractures

Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease

A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals

A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea

Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)

Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT)

A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization

The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)

Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT)